Discontinuing the public posting of Initial Inspection Deficiencies in the Drug and Health Products Inspections Database
Drug Establishment Licensing Bulletin 197, October 26, 2026
On this page
About the changes
Health Canada is discontinuing the public posting of Initial Inspection Deficiencies (IIDs) in the Drug and Health Products Inspections Database (DHPID) for:
- drug Good Manufacturing Practices (GMP) inspections
- natural health products (NHP) GMP inspections
- Good Pharmacovigilance Practices (GVP) inspections
Drug and Health Products Inspections Database (DHPID)
This change supports a more consistent and meaningful approach to inspection transparency by focusing on substantiated regulatory compliance information and definitive inspection findings.
Health Canada publishes inspection information to support transparency and public confidence in the regulatory oversight of drug and health product establishments. IIDs summarize deficiencies identified during an inspection. They are posted before we have finalized inspection observations.
Since the introduction of IIDs in 2015, Health Canada has gained experience with the publication of inspection information and the needs of stakeholders. During this time, inspection report cards and final inspection outcomes have become established transparency tools. They provide more complete and contextualized information on inspection results and regulatory oversight than IIDs. As a result, Health Canada is focusing its public reporting on finalized inspection outcomes. These finalized inspection outcomes better reflect the final regulatory assessment and provide stakeholders with information that is accurate, validated and interpretable.
Discontinuing public IID postings will:
- align inspection transparency practices across the affected inspection programs
- refine, rather than reduce, transparency by ensuring that publicly available information reflects completed regulatory assessments
What this means for you
- Public posting of IIDs will be discontinued effective October 21, 2026.
- Health Canada will no longer publicly post IIDs in the DHPID for drug GMP, NHP GMP and GVP inspection programs.
- Public reporting of finalized compliance outcomes remains unchanged.
- Health Canada will continue to publicly report inspections conducted and finalized compliance outcomes, including compliant and non-compliant ratings, through existing transparency mechanisms.
- Public reporting will focus on finalized inspection outcomes.
- Health Canada will continue to report finalized compliance outcomes, which provide accurate, validated and interpretable information.
Contact us
If you have any questions, contact the Health Product Inspection and Licensing Division of the Regulatory Operations and Enforcement Branch by email:
- Drug GMP questions: drug.gmp.questions-bpf.medicaments@hc-sc.gc.ca
- NHP: hpcrm.nhpinspection-inspectionpsn.cpsgr@hc-sc.gc.ca
- GVP: gvp-bpv@hc-sc.gc.ca